Trial Profile

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Temozolomide (Primary) ; Carboplatin; Cisplatin; Etoposide
Indications Gastric cancer; Neuroendocrine carcinoma; Pancreatic cancer
Focus Therapeutic Use

29 Dec 2025 Actual primary completion date is 23 Apr 2025.
18 Mar 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Sep 2025.
10 Dec 2024 Planned primary completion date changed from 1 Jan 2025 to 30 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com